Interactions Between Drugs and Occupied Receptors

Overview

Journal Pharmacol Ther

Specialty Pharmacology

Date 2006 Nov 3

PMID 17079019

Citations 61

Authors

Ronald J Tallarida

Affiliations

Soon will be listed here.

Abstract

This review has 2 parts. Part I deals with isobolographic procedures that are traditionally applied to the joint action of agonists that individually produce overtly similar effects. Special attention is directed to newer computational procedures that apply to agonists with dissimilar concentration-effect curves. These newer procedures are consistent with the isobolographic methods introduced and used by Loewe, however, the present communications provides the needed graphical and mathematical detail. A major aim is distinguishing super and sub-addictive interactions from those that are simply additive. The detection and measurement of an interaction is an important step in exploring drug mechanism and is also important clinically. Part II discusses a new use of isoboles that is applicable to a single drug or chemical whose effect is mediated by 2 or more receptor subtypes. This application produces a metric that characterizes the interaction between the receptor subtypes. The expansion of traditional isobolographic theory to this multi-receptor situation follows from the newer approaches for 2-drug combination analysis in Part I. This topic leads naturally to a re-examination of competitive antagonism and the classic Schild plot. In particular, it is shown here that the Schild plot in the multi-receptor case is not necessarily linear with unit slope. Both parts of this review emphasize the quantitative aspects rather than the many drugs that have been analyzed with isobolographic methods. The mathematical exposition is rather elementary and is further aided by several graphs. An appendix is included for the reader interested in the mathematical details.

Citing Articles

Ivermectin Strengthens Paclitaxel Effectiveness in High-Grade Serous Carcinoma in 3D Cell Cultures.

Nunes M, Ricardo S Pharmaceuticals (Basel). 2025; 18(1.

PMID: 39861076 PMC: 11769219. DOI: 10.3390/ph18010014.

Schild Analysis of the Interaction between Parthenolide and Cocaine Suggests an Allosteric Relationship for Their Effects on Planarian Motility.

Kakuturu J, OBrien M, Pagan O Biomolecules. 2024; 14(9).

PMID: 39334934 PMC: 11430750. DOI: 10.3390/biom14091168.

AM1172 (a hydrolysis-resistant endocannabinoid analog that inhibits anandamide cellular uptake) reduces the viability of the various melanoma cells, but it exerts significant cytotoxic effects on healthy cells: an in vitro study based on....

Marzeda P, Wroblewska-Luczka P, Florek-Luszczki M, Goralczyk A, Luszczki J Pharmacol Rep. 2023; 76(1):154-170.

PMID: 38019413 PMC: 10830817. DOI: 10.1007/s43440-023-00557-2.

Imperatorin interacts additively with novel antiseizure medications in the mouse maximal electroshock-induced seizure model: an isobolographic transformation.

Luszczki J, Kochman-Moskal E, Bojar H, Florek-Luszczki M, Skalicka-Wozniak K Pharmacol Rep. 2023; 76(1):216-222.

PMID: 38015370 PMC: 10830790. DOI: 10.1007/s43440-023-00555-4.

The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line.

Nunes M, Duarte D, Vale N, Ricardo S Int J Mol Sci. 2023; 24(1).

PMID: 36613537 PMC: 9820586. DOI: 10.3390/ijms24010097.

References

Choppin A, Eglen R . Pharmacological characterization of muscarinic receptors in mouse isolated urinary bladder smooth muscle. Br J Pharmacol. 2001; 133(7):1035-40. PMC: 1572871. DOI: 10.1038/sj.bjp.0704165. View

Difazio C, Brown R, Ball C, Heckel C, Kennedy S . Additive effects of anesthetics and theories of anesthesia. Anesthesiology. 1972; 36(1):57-63. DOI: 10.1097/00000542-197201000-00010. View

ARUNLAKSHANA O, SCHILD H . Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959; 14(1):48-58. PMC: 1481829. DOI: 10.1111/j.1476-5381.1959.tb00928.x. View

Tallarida R . The interaction index: a measure of drug synergism. Pain. 2002; 98(1-2):163-8. DOI: 10.1016/s0304-3959(02)00041-6. View

LOEWE S . The problem of synergism and antagonism of combined drugs. Arzneimittelforschung. 1953; 3(6):285-90. View

Wessinger W . Approaches to the study of drug interactions in behavioral pharmacology. Neurosci Biobehav Rev. 1986; 10(2):103-13. DOI: 10.1016/0149-7634(86)90021-7. View

Tallarida R . Commentary on neostigmine interactions with non steroidal anti-inflammatory drugs by Miranda et al. Br J Pharmacol. 2002; 135(7):1589-90. PMC: 1573280. DOI: 10.1038/sj.bjp.0704600. View

Raffa R, Friderichs E, Reimann W, Shank R, Codd E, Vaught J . Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther. 1993; 267(1):331-40. View

Eglen R, Whiting R . Estimation of apparent agonist affinity constants using desensitization of the ileal muscarinic receptor. J Pharmacol Exp Ther. 1987; 240(2):404-9. View

10.

Grabovsky Y, Tallarida R . Isobolographic analysis for combinations of a full and partial agonist: curved isoboles. J Pharmacol Exp Ther. 2004; 310(3):981-6. DOI: 10.1124/jpet.104.067264. View

11.

Raffa R, Stone Jr D, Tallarida R . Discovery of "self-synergistic" spinal/supraspinal antinociception produced by acetaminophen (paracetamol). J Pharmacol Exp Ther. 2000; 295(1):291-4. View

12.

Field M, Gonzalez M, Tallarida R, Singh L . Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. J Pharmacol Exp Ther. 2002; 303(2):730-5. DOI: 10.1124/jpet.102.033134. View

13.

Gessner P, CABANA B . A study of the interaction of the hypnotic effects and of the toxic effects of chloral hydrate and ethanol. J Pharmacol Exp Ther. 1970; 174(2):247-59. View

14.

SCHILD H . pA, a new scale for the measurement of drug antagonism. Br J Pharmacol Chemother. 2010; 2(3):189-206. PMC: 1509780. DOI: 10.1111/j.1476-5381.1947.tb00336.x. View

15.

Bolan E, Tallarida R, Pasternak G . Synergy between mu opioid ligands: evidence for functional interactions among mu opioid receptor subtypes. J Pharmacol Exp Ther. 2002; 303(2):557-62. DOI: 10.1124/jpet.102.035881. View

16.

Rawls S, Cowan A, Tallarida R, Geller E, Adler M . N-methyl-D-aspartate antagonists and WIN 55212-2 [4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1-i,j]quinolin-6-one], a cannabinoid agonist, interact to produce synergistic hypothermia. J Pharmacol Exp Ther. 2002; 303(1):395-402. DOI: 10.1124/jpet.102.037473. View

17.

Tallarida R, Cowan A, Adler M . pA2 and receptor differentiation: a statistical analysis of competitive antagonism. Life Sci. 1979; 25(8):637-54. DOI: 10.1016/0024-3205(79)90505-8. View

18.

BERENBAUM M . What is synergy?. Pharmacol Rev. 1989; 41(2):93-141. View

19.

Tallarida R . Drug synergism: its detection and applications. J Pharmacol Exp Ther. 2001; 298(3):865-72. View

20.

Tallarida R, Cowan A, Raffa R . Antinociceptive synergy, additivity, and subadditivity with combinations of oral glucosamine plus nonopioid analgesics in mice. J Pharmacol Exp Ther. 2003; 307(2):699-704. DOI: 10.1124/jpet.103.054320. View